TC BioPharm News - TCBP

Company Name	Stock Ticker Symbol	Market	Type
TC BioPharm Holdings PLC	TCBP	NASDAQ	Depository Receipt

	Price Change	Change Percent	Stock Price	Last Traded
	0.00	0.00%	0.9501	07:00:00

Open Price	Low Price	High Price	Close Price	Prev Close
				0.9501

more quote information »

Recent News

Date	Time	Source	Heading
5/15/2024	08:30	PRNUS	TCBP Announces Launch of Compassionate Use Program for..
5/06/2024	13:01	PRNUS	TC BioPharm Announces Exercise of Warrants for £3.1 Million..
5/06/2024	08:30	PRNUS	TC BioPharm Announces Execution of Second Non-Binding Letter..
4/04/2024	08:32	PRNUS	TCBP Announces Execution of Non-Binding Letter of Intent for..
4/02/2024	08:30	PRNUS	TCBP Increasing Treatment Capacity with Expanded..
3/19/2024	08:30	PRNUS	TCBP Adjourns General Meeting Until a Later Date
3/18/2024	08:30	PRNUS	TCBP Announces Exercise of Series D Warrants For Cash
3/06/2024	06:30	EDGAR2	Form 8-K - Current report
3/01/2024	08:30	PRNUS	Bryan Kobel, CEO of TCBP, Appears on Nationally Syndicated..
2/27/2024	17:15	PRNUS	/C O R R E C T I O N -- TC BioPharm/
2/27/2024	08:30	PRNUS	TCBP Announces Shareholder Update Call on March 5th 2024
2/22/2024	09:32	PRNUS	TCBP Announces MHRA Acceptance of Amendment for ACHIEVE UK..
2/20/2024	06:05	EDGAR2	Form DEF 14A - Other definitive proxy statements
2/15/2024	08:30	PRNUS	TC BioPharm Management to Participate at Upcoming 7th..
2/14/2024	14:48	EDGAR2	Form 8-K - Current report
2/14/2024	08:30	PRNUS	TCBP Provides Shareholder Update and Highlights Upcoming..
2/09/2024	15:26	EDGAR2	Form PRE 14A - Other preliminary proxy statements
1/29/2024	09:16	EDGAR2	Form SC 13G/A - Statement of acquisition of beneficial..
1/29/2024	08:30	PRNUS	TC BioPharm Chief Executive Officer, Bryan Kobel Featured on..
1/18/2024	08:30	PRNUS	TC BioPharm to Present at the Sequire Investor Summit
1/04/2024	08:46	EDGAR2	Form 8-K - Current report
1/04/2024	08:30	PRNUS	TC BioPharm Regains Compliance with Nasdaq Minimum Bid Price..
1/03/2024	08:30	PRNUS	TC BioPharm Announces Additional Cost Reduction Steps to..
12/22/2023	08:30	PRNUS	TC BioPharm Announces Closing of $3.5 Million Public..
12/21/2023	17:14	EDGAR2	Form 6-K - Report of foreign issuer [Rules 13a-16 and..
12/19/2023	08:00	PRNUS	TC BioPharm Announces Pricing of $3.5 Million Public..
12/19/2023	00:15	EDGAR2	Form EFFECT - Notice of Effectiveness
12/18/2023	11:15	PRNUS	TC BioPharm Announces Formation of Commercial Development..
12/14/2023	17:20	EDGAR2	Form F-1/A - Registration statement for certain foreign..
12/13/2023	09:05	EDGAR2	Form 6-K - Report of foreign issuer [Rules 13a-16 and..
12/13/2023	06:30	PRNUS	TC BioPharm Announces Plan to Implement ADS Ratio Change
11/27/2023	08:45	PRNUS	TC BioPharm Announces FDA Clearance of Phase 1B IND for..
11/14/2023	10:00	PRNUS	TC BioPharm Announces Successful Completion of Safety Cohort..
11/08/2023	16:05	EDGAR2	Form 424B3 - Prospectus [Rule 424(b)(3)]
11/02/2023	13:30	PRNUS	TC BioPharm Announces Streamlined Efficiencies and Reduces..
11/02/2023	13:11	EDGAR2	Form F-3/A - Registration statement by foreign private..
11/02/2023	12:57	EDGAR2	Form 6-K - Report of foreign issuer [Rules 13a-16 and..
10/25/2023	08:00	PRNUS	TC BioPharm Selects Excellos as CDMO in Anticipation of..
10/23/2023	08:00	PRNUS	TC BioPharm Announces Submission of Investigational New Drug..
9/29/2023	16:05	EDGAR2	Form F-3 - Registration statement by foreign private issuers
9/27/2023	08:00	PRNUS	TC BioPharm to Present at the LD Micro Main Event XVI
9/05/2023	08:30	PRNUS	TC BioPharm Announces Grant Funding in Collaboration with..
9/01/2023	17:15	EDGAR2	Form 424B3 - Prospectus [Rule 424(b)(3)]
8/31/2023	08:00	EDGAR2	Form 6-K - Report of foreign issuer [Rules 13a-16 and..
8/29/2023	08:30	PRNUS	TC BioPharm to Present at H.C. Wainwright 25th Annual Global..
8/28/2023	17:25	EDGAR2	Form F-1 - Registration statement for certain foreign..
8/22/2023	16:10	EDGAR2	Form 6-K - Report of foreign issuer [Rules 13a-16 and..
7/31/2023	08:30	PRNUS	TC BioPharm Maintains Nasdaq Listing
7/31/2023	08:15	EDGAR2	Form 6-K - Report of foreign issuer [Rules 13a-16 and..
7/24/2023	16:05	EDGAR2	Form 6-K - Report of foreign issuer [Rules 13a-16 and..